STOPNET Trial: A randomised study of cessation of Somatostatin analogues after Peptide Receptor Radionucleotide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine tumours.
The trial aims to evaluate the outcomes of Somatostatin analogue (SSA) cessation in patients with neuroendocrine tumours after Peptide Receptor Radionuclide Therapy (PRRT).
Study protocol: Not published
ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06345079
ClinicalTrials.gov ID: NCT06345079
STOPNET is coordinated by the AGITG Clinical Research Centre (CRC) in collaboration with the Canadian Cancer Trials Group (CCTG) under the Commonwealth Neuroendocrine Tumor research collaborative (CommNETS).
Key features of the AGITG approach
Embedded from the outset: The teletrial model was embedded in the study protocol from the outset to provide guidance to sites and ensure a seamless and successful rollout as an integral part of the trial.
Early engagement with teletrial partners: The respective Australian Teletrial Program (ATP) Regional Clinical Trial Coordinating Centre (RCCC) was included on the study feasibility survey email to enable collaboration and provide the opportunity to consider the study in that region and patient population in the preliminary stages.
Support for sites: The STOPNET study team met with RCCC’s interested in the study to understand the teletrial roadmap and process for implementation at the interested sites that they could support.
Successful cases employing the teletrial model include:
- Queensland (QLD) state-wide teletrial cluster model: Ethical approval was granted by the Metro North Health Human Research Ethics Committee (HREC) with the Royal Brisbane and Women’s Hospital as the primary site. The approval allowed any health service in QLD to be included as a satellite site under this approval. Local Governance at the Satellite site was facilitated by the QLD RCCC who were engaged from the outset.
- In Western Australia (WA) the STOPNET study team facilitated discussions between Fiona Stanley Hospital and the WA RCCC to implement its first teletrial, with Kalgoorlie Health Campus as a satellite site.
AGITG provided travel support funding for participants identified in regional, rural and remote Australia. This has proven extremely valuable and a fundamental factor for participant consideration and access to clinical trials. To date, a substantial portion of participants screened have accessed this opportunity.
This case is part of ACTA’s teletrials web resource which includes more examples of how Clinical Trial Networks (CTNs) and Coordinating Trial Centres (CTCs) have used the teletrial approach in their trials.
Find out more
Please contact the AGITG team:
Dr Matthew Burge, PI
E: Matthew.Burge@health.qld.gov.au
Amy Ives, Cancer Trials Manager, RBWH, Qld
E: Amy.Ives@health.qld.gov.au